Revolution Medicines Inc. - RVMD

Revolution Medicines Inc. is a clinical-stage precision oncology company focused on developing targeted cancer therapies. The company concentrates on inhibiting difficult-to-drug molecular targets within key cell growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways that are frequently altered in solid tumors. Its pipeline includes RMC-4630, a SHP2 inhibitor designed to disrupt signaling that supports tumor growth, as well as a portfolio of RAS(ON) inhibitors and programs targeting SOS1 and 4EBP1/mTORC1. These investigational therapies are being studied as both monotherapies and in combinations to address cancers driven by RAS and related pathway alterations. Revolution Medicines serves the biopharmaceutical and oncology treatment markets by discovering and advancing molecules intended for use in cancer care, typically in collaboration with healthcare providers and research centers. Founded in 2004 and headquartered in Redwood City, California, Revolution Medicines operates within the biotechnology sector, contributing to the development of next-generation targeted oncology drugs.